Furthermore, SGLT2 inhibitors were found to reduce the risk of renal disease progression by 45%, and show similar benefits for patients with and without established cardiovascular disease in a systematic review and meta-analysis [7]. This evidence concerns the gene SLC5A2 and cardiovascular disorder.